Fate Therapeutics Inc
Change company Symbol lookup
Select an option...
FATE Fate Therapeutics Inc
WES Western Midstream Partners LP
BAC Bank of America Corp
UNH UnitedHealth Group Inc
MSFT Microsoft Corp
BWA BorgWarner Inc
PAC Grupo Aeroportuario del Pacifico SAB de CV
AAPL Apple Inc
SPH Suburban Propane Partners LP
PH Parker-Hannifin Corp
Go

Health Care : Biotechnology | Small Cap Growth
Company profile

Fate Therapeutics, Inc. (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company's cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity. Its lead clinical program is ProTmune, which is a programmed immuno-regulatory cell therapy. The Company programs immune cells, such as CD34+ cells, Natural Killer (NK) cells and T cells, by utilizing its cell programming approach. Its adoptive cell therapy programs are based on the Company's ex vivo cell programming approach, which it applies to modulate the therapeutic function and direct the fate of immune cells.

Postmarket

Last Trade
Delayed
$29.20
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$29.20
Day's Change
0.41 (1.42%)
Bid close
--
Ask close
--
B/A Size
--
Day's High
29.34
Day's Low
27.08
Volume
(Heavy Day)
Volume:
1,831,053

10-day average volume:
901,533
1,831,053

UPDATE: AT&T's stock soars after activist investors outlines plan to boost shares by over 65%

8:06 am ET September 9, 2019 (MarketWatch)
Print

Shares of AT&T Inc. (T) soared 8.4% in premarket trading Monday, after activist investor Elliott Management outlined a "value-creation opportunity" that it believes could lift the telecom and media giant's stock by more than 65% to a record high. Elliott, which manages funds that beneficially own $3.2 billion worth of AT&T stock, which is about 1.2% of AT&T's $264.9 billion in market capitalization as of Friday's stock closing price of $36.25, said the stock is "deeply undervalued," as the company's "world-class collection of assets" are priced at historically discounted levels. Elliott says its "Activating AT&T Plan" recommends increased strategic focus, improved operational efficiency, a formal capital allocation framework and enhanced leadership and oversight. Elliott believes its plan could lift the stock price to above $60 by the end of 2021, which would be above the July 16, 1999 record close of $59.19, and 65.5% above Friday's close. AT&T's stock has gained 12.9% over the past 12 months, while the SPDR Communication Services Select Sector ETF (XLC) has tacked on 6.4% and the S&P 500 has gained 3.7%.

-Tomi Kilgore; 415-439-6400; AskNewswires@dowjones.com

(END) Dow Jones Newswires

September 09, 2019 08:06 ET (12:06 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.